LLY

1,010.29

-0.77%↓

JNJ

247.77

-0.21%↓

ABBV

235.04

+0.67%↑

NVS

164.41

-1.49%↓

MRK

120.52

-0.8%↓

LLY

1,010.29

-0.77%↓

JNJ

247.77

-0.21%↓

ABBV

235.04

+0.67%↑

NVS

164.41

-1.49%↓

MRK

120.52

-0.8%↓

LLY

1,010.29

-0.77%↓

JNJ

247.77

-0.21%↓

ABBV

235.04

+0.67%↑

NVS

164.41

-1.49%↓

MRK

120.52

-0.8%↓

LLY

1,010.29

-0.77%↓

JNJ

247.77

-0.21%↓

ABBV

235.04

+0.67%↑

NVS

164.41

-1.49%↓

MRK

120.52

-0.8%↓

LLY

1,010.29

-0.77%↓

JNJ

247.77

-0.21%↓

ABBV

235.04

+0.67%↑

NVS

164.41

-1.49%↓

MRK

120.52

-0.8%↓

Search

Alvotech SA

Open

SectorGezondheidszorg

3.82 -2.55

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.65

Max

3.93

Belangrijke statistieken

By Trading Economics

Inkomsten

-37M

-5.3M

Verkoop

-59M

114M

K/W

Sectorgemiddelde

18.348

108.767

EPS

-0.017

Winstmarge

-4.609

Werknemers

1,012

EBITDA

-48M

3.7M

Aanbevelingen

By TipRanks

Aanbevelingen

Sell

12 Maanden Prognose

+26.26% upside

Dividenden

By Dow Jones

Volgende Winsten

18 mrt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-405M

1.3B

Vorige openingsprijs

6.37

Vorige sluitingsprijs

3.82

Nieuwssentiment

By Acuity

37%

63%

97 / 352 Rangschikking in Healthcare

Alvotech SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 nov 2025, 15:14 UTC

Belangrijke Marktbewegers

Alvotech Shares Slide on FDA Demands for Application for Arthritis Drug Biosimilar

15 apr 2025, 14:54 UTC

Winsten

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

Peer Vergelijking

Prijswijziging

Alvotech SA Prognose

Koersdoel

By TipRanks

26.26% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5 USD  26.26%

Hoogste 5 USD

Laagste 5 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Alvotech SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Sell

1 ratings

0

Buy

0

Hold

1

Sell

Sentiment

By Acuity

97 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
help-icon Live chat